Table SI. Study quality assessment using the Newcastle–Ottawa Scale

Author	Selection	Comparability	Outcome/exposure	Total	Study
Liao et al.	★★★★	★★	★★★	9	RCT
Lebwohl et al.	★★★★	★★	★★★	9	RCT
Kleyn et al.	★★★★	★	★★★	8	RCT
Kreuter et al.	★★★★	★★	★★★	9	RCT
Gribetz et al.	★★★★	★★	★★★	9	RCT
Bissonette et al.	★★★	-	★★★	6	OPL
Rallis et al.	★★★	-	★★★	6	OPL
Freeman et al.	★★★	-	★★★	6	OPL
Brune et al.	★★	-	★★★	5	OPL
Yamamoto et al.	★★★	-	★★★	6	OPL
Yamamoto et al.	★★★	-	★★★	6	OPL
Ezquerra et al.	★★★	-	★★★	6	OPL
Jacobi et al.	★★★	-	★★★	6	OPL
Frigerio et al.	★★★	-	★★★	6	OPL

OPL: Open-label study; RCT: Randomized Controlled Trial.

Table SII. Safety of tacrolimus in the treatment of facial and genital psoriasis

Author & country	No. of patients	Itching	Warmth sensation	Stinging/burning	Other
Liao et al. (25) Taiwan	49	-	Tacrolimus 0.03%: 4 % Calcitriol 0.0003%: 4 %	Tacrolimus 0.03%: 4 % Calcitriol 0.0003%: -	Tacrolimus 0.03% / Calcitriol 0.0003% / p-value Perilesional erythema: 16 % / 58 % / *p=0.004* Perilesional edema: - / 4 % Folliculitis/acne: 4% / - IGT[a] excellent tolerance: 92% / 92%
Lebwohl et al. (40) USA	167	Tacrolimus 0.1%: 7 % Vehicle: 2 % p-value: *p=0.27*	-	Tacrolimus 0.1%: 8 % Vehicle: 7 % p-value: *p=1.00*	Tacrolimus 0.1% / Vehicle / p-value Hyperesthesia: 5 % / - / *p=0.17*
Kleyn et al. (30) UK	28	Tacrolimus 0.1%: 4 % Clobetasone butyrate 0.05%: 7 %	-	Tacrolimus 0.1%: 14 % Clobetasone butyrate 0.05%: 7 %	Flushing Tacrolimus 0.1%: 4 % Clobetasone butyrate 0.05%: 7 %
Bisonette et al.(37) Canada	12	Tacrolimus 0.1%: 17 %	-	Tacrolimus 0.1%: 41 %	-
Rallis et al. (28) Greece	10	-	-	-	No adverse effects
Freeman et al.(39) USA	21	Tacrolimus 0.1%: 5 %	Tacrolimus 0.1%: 5 %	-	-
Brune et al.(41) USA	11	Tacrolimus 0.1%: 9 %	-	-	-

Yamamoto et al. (23) Japan	21	-	-	-	Tingling Tacrolimus 0.1% 19 %
Yamamoto et al. (24) Japan	11	-	-	-	No local adverse effects. No adverse effects on liver or renal function were noted
Ezquerra et al. (33) Spain	15	-	Tacrolimus 0.1% 13 %	-	-
Steele et al. (42) USA	13	-	-	Tacrolimus 0.1% 8 %	
Yamamoto et al.(22) Japan	2	-	-	-	No adverse effects were noted
Yamamoto et al. (19) Japan	1	-	-	-	Deep dermatophytosis with tinea corporis.

IGT: Investigator's global tolerance of target area.

[a]IGT: Scale 0-2 (poor, good, excellent) based on perilesional erythema, perilesional edema, mild/moderate stinging burning, folliculitis/acne breakout.

Table SIII. Safety of pimecrolimus in the treatment of facial and genital psoriasis

Author & Country	No. of patients	Itching				Warmth sensation				Stinging/burning				Other			
Kreuter et al. (26) Germany	80	Pimecrolimus 1%	Calcipotriol 0.005%	Betamethasone 0.1%	Vehicle	Pimecrolimus 1%	Calcipotriol 0.005%	Betamethasone 0.1%	Vehicle	Pimecrolimus 1%	Calcipotriol 0.005%	Betamethasone 0.1%	Vehicle	Pimecrolimus 1%	Calcipotriol 0.005%	Betamethasone 0.1%.	Vehicle
		25 %	-	-	-	-	10 %	-	-	25 %	-	-	-	Ertyhema			
														-	10 %	-	-
														Herpes genitalis			
														-	-	-	5 %
Gribetz et al. (38) USA	57	-				-				-				Pimecrolimus 1%			Vehicle
														Paresthesia			
														4 %			-
														Tenderness			
														-			3 %
Jacobi et al. (27) Germany	20	-				Pimecrolimus 1%				-				-			
						10 %											
Frigerio et al(31) Italy	40	Pimecrolimus 1%				-				Pimecrolimus 1%				-			
		2.5 %								2.5 %							
Canpolat et al. (20) Turkey	1	-				-				-				No adverse effects were observed.			